Pena Luis C. 4

What Happened

• Luis C. Pena, President & CEO and Director of Evommune, was granted a derivative award of 291,420 shares on 2026-04-16. The Form 4 records the acquisition at $0.00 (total $0) and lists the transaction as a grant (transaction code A), meaning this is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-16; Form filed: 2026-04-17 (timely filing).
• Shares granted: 291,420; reported price: $0.00; reported total value: $0 on the Form 4.
• Vesting: One-fourth (25%) vests on the first anniversary of the grant; the remaining shares vest in 36 equal monthly installments thereafter, subject to continued service (per footnote).
• Nature: Recorded as a derivative/option award per the filing footnote.
• Shares owned after transaction: Not specified in the provided Form 4.
• No 10b5-1 plan, tax-withholding sale, or other special instructions were noted beyond the vesting schedule.

Context

• This is a time‑based compensation grant (option/award) that vests over four years and does not reflect an immediate market purchase or sale. Such grants are common for executive compensation; they only affect outstanding share count or insider holdings if and when exercised/issued or sold.